TwinBeech Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

TwinBeech Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-28,173	Closed	-$1.45M	–	968
2025 Q1	$1.45M	Buy	+28,173	New	+$1.39M	0.03%	432
2024 Q3	–	Sell	-54,152	Closed	-$1.47M	–	879
2024 Q2	$1.47M	Buy	+54,152	New	+$1.82M	0.03%	364

Other funds holding TARS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TwinBeech Capital's TARS Position: Q2 2025 in Review

TwinBeech Capital sold out of Tarsus Pharmaceuticals (TARS) in Q2 2025, closing a stake of 28,173 shares — an estimated $1.45M sold.

TwinBeech Capital first reported a position in TARS in Q2 2024 and held it in 2 quarters. The position peaked at $1.47M in Q2 2024. 205 funds tracked by Wall St. Rank hold TARS as of Q2 2025.

TwinBeech Capital reported no remaining Tarsus Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
TwinBeech Capital sold 28,173 Tarsus Pharmaceuticals shares in Q2 2025, an estimated $1.45M.
TwinBeech Capital first reported a position in Tarsus Pharmaceuticals in Q2 2024 and held it in 2 quarters.
TwinBeech Capital's Tarsus Pharmaceuticals position peaked at $1.47M in Q2 2024.
205 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2025.

Based on TwinBeech Capital's 13F filing for Q2 2025, filed 14 Aug 2025.